Welcome to our dedicated page for Syndax Pharmaceuticals news (Ticker: SNDX), a resource for investors and traders seeking the latest updates and insights on Syndax Pharmaceuticals stock.
Syndax Pharmaceuticals reports developments as a commercial-stage biopharmaceutical company advancing cancer therapies. Company updates center on Revuforj (revumenib), an FDA-approved menin inhibitor, and Niktimvo (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 receptor.
Recurring news includes quarterly financial results, product revenue for Revuforj and Niktimvo, collaboration revenue from Niktimvo commercialization with Incyte, clinical data presentations in acute leukemia, chronic graft-versus-host disease and related indications, FDA-related product updates, investor conference activity and inducement equity grants under Nasdaq listing rules.
Syndax Pharmaceuticals will release its Q2 2020 financial results on August 6, 2020, after U.S. market close. The management team will hold a conference call and live audio webcast at 4:30 p.m. ET on the same day to discuss the results and provide a business update. Investors can access the webcast on the company's website. Syndax is developing a pipeline of cancer therapies, including drug candidates SNDX-5613, axatilimab, and entinostat.
Syndax Pharmaceuticals has appointed Daphne Karydas as Chief Financial Officer, effective July 13, 2020. Karydas has nearly 20 years of experience in the biopharmaceutical sector, serving most recently at Allergan. She replaces Richard P. Shea, who is retiring. CEO Briggs W. Morrison expressed confidence in Karydas’ ability to drive long-term growth as the company advances key drug programs, including SNDX-5613 and axatilimab, with critical readouts expected in Q4 2020. Karydas aims to leverage her expertise to improve patient outcomes in cancer care.